← Back to headlines
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
6 Mar, 02:07 — 6 Mar, 02:07
Sources
Showing 1 of 1 sources
Related Stories
Longeveron anticipates August 2026 ELPIS II readout while shifting to asset-light model
18m ago
QT Imaging projects $39M 2026 revenue outlook as AMA CPT code takes effect
18m ago
Hawke's Bay youth design healthy eating guidelines and launch social media campaign
22m ago
UK Health Secretary Wes Streeting Dominates Front Pages Amidst Political Scrutiny
25m ago